

# Rapid Point-of-Care Isothermal Amplification Assay for the Detection of Malaria without Nucleic Acid Purification

Sayli S. Modak<sup>1</sup>, Cheryl A. Barber<sup>1</sup>, Eran Geva<sup>1</sup>, William R. Abrams<sup>1</sup>, Daniel Malamud<sup>1,2</sup> and Yhombi Serge Yvon Ongagna<sup>1</sup>

<sup>1</sup>Department of Basic Science, New York University College of Dentistry, New York, NY, USA. <sup>2</sup>Department of Medicine, New York University Langone School of Medicine, New York, NY, USA.

**ABSTRACT:** Malaria remains one of the most prevalent infectious diseases and results in significant mortality. Isothermal amplification (loop-mediated isothermal amplification) is used to detect malarial DNA at levels of ~1 parasite/μL blood in ≤30 minutes without the isolation of parasite nucleic acid from subject's blood or saliva. The technique targets the mitochondrial cytochrome oxidase subunit 1 gene and is capable of distinguishing *Plasmodium falciparum* from *Plasmodium vivax*. Malarial diagnosis by the *gold standard* microscopic examination of blood smears is generally carried out only after moderate-to-severe symptoms appear. Rapid diagnostic antigen tests are available but generally require infection levels in the range of 200–2,000 parasites/μL for a positive diagnosis and cannot distinguish if the disease has been cleared due to the persistence of circulating antigen. This study describes a rapid and simple molecular assay to detect malarial genes directly from whole blood or saliva without DNA isolation.

**KEYWORDS:** malaria, point-of-care (POC), loop-mediated isothermal amplification (LAMP), molecular detection, *Plasmodium falciparum*, *Plasmodium vivax*

**CITATION:** Modak et al. Rapid Point-of-Care Isothermal Amplification Assay for the Detection of Malaria without Nucleic Acid Purification. *Infectious Diseases: Research and Treatment* 2016;9 1–9 doi:10.4137/IDRT.S32162.

**TYPE:** Original Research

**RECEIVED:** September 7, 2015. **RESUBMITTED:** November 25, 2015. **ACCEPTED FOR PUBLICATION:** November 27, 2015.

**ACADEMIC EDITOR:** Douglas MacPherson, Editor in Chief

**PEER REVIEW:** Five peer reviewers contributed to the peer review report. Reviewers' reports totaled 1739 words, excluding any confidential comments to the academic editor.

**FUNDING:** Funding for this project was received from the National Institute of Dental and Craniofacial Research Grants U01DE017855 and R44DE024456. The authors confirm that the funder had no influence over the study design, content of the article, or selection of this journal.

**COMPETING INTERESTS:** Authors disclose no potential conflicts of interest.

**COPYRIGHT:** © the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.

**CORRESPONDENCE:** daniel.malamud@nyu.edu

Paper subject to independent expert blind peer review. All editorial decisions made by independent academic editor. Upon submission manuscript was subject to anti-plagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with any copyright requirements of third parties. This journal is a member of the Committee on Publication Ethics (COPE). Provenance: the authors were invited to submit this paper.

Published by Libertas Academica. Learn more about this journal.

## Introduction

In 2013, there were almost 200 million malarial infections that resulted in approximately one-half million deaths, 90% of which occurred in Africa.<sup>1</sup> A practical alternative to the vaccination approach<sup>2</sup> to eradicate malaria is the *Test-and-Treat* paradigm currently being evaluated for the eradication of HIV,<sup>3</sup> which predicts that if all symptomatic and asymptomatic individuals in a region are tested and all of those who test positive are immediately treated, the burden of disease in that area will decrease. We believe that the same approach is feasible for malaria by deploying an inexpensive point-of-care (POC) diagnostic test for *Plasmodium* DNA followed by appropriate therapeutic intervention. Currently, malaria is detected by (1) microscopic examination of thick and thin blood smears, a laborious process that is time-consuming and requires trained personnel; (2) laboratory-based polymerase chain reaction (PCR) tests, which are expensive, time-consuming, and require specialized equipment and trained personnel; or (3) rapid antigen-based tests (RDTs), which are generally less sensitive.

Commercially available RDTs for malarial antigens were first introduced in 1994 and are readily available. The World Health Organization has noted the shortcomings of the available RDTs to include (1) poor quality of some products, (2) inability to

detect mutant forms of plasmodia that have deleted the histidine-rich protein 2 target gene, (3) low sensitivity (500–1,000 parasites/μL), and (4) false-positive results long after the infection is cleared due to residual antigen in the bloodstream.<sup>1</sup>

Isothermal nucleic acid amplification methods such as loop-mediated isothermal amplification (LAMP) make use of a polymerase with built-in strand displacement capabilities which does not require a high-temperature denaturation step such as conventional PCR and loop primers to increase the sensitivity. This is a major advantage for POC devices since the entire amplification reaction typically occurs under isothermal conditions at 65°C. The progress of the real-time reaction can be visualized using an intercalating fluorescent dye such as SYBR Green, which preferentially binds to double-stranded DNA. Our goal was to design a POC LAMP nucleic acid test for the detection of parasites using both blood and oral fluid, and it requires no sample purification. The assay is completed in 30 minutes with a sensitivity 10–100-fold greater than conventional PCR<sup>4,5</sup> and 500–1,000 times more sensitive than antigen detection. Other investigators have reported the detection of malarial DNA extracted from blood, saliva, or urine samples,<sup>6–9</sup> but mostly utilized purified parasite DNA. Previous reports using LAMP targeted a conserved sequence



in parasite 18S rRNA.<sup>9–11</sup> However, we report here that targeting the mitochondrial cytochrome C oxidase subunit 1 gene improves the assay's specificity and unlike previously described assays can discriminate between *Plasmodium falciparum* and *Plasmodium vivax* infection.<sup>12,13</sup>

## Methods

**Malaria-positive blood.** The following reagents were obtained through the Malaria Research and Reference Reagent Resource Center (MR4) as part of the Biodefense and Emerging Infections Research Resources Repository (BEI Resources), National Institute of Allergy and Infectious Diseases (NIAID), and National Institute of Health: *P. falciparum* FCR-3/Gambia Subline F-86, MRA-731, deposited by W Trager; *P. falciparum* GB4, MRA-925, deposited by Karen Hayton, Tom Wellems (NIAID); *P. falciparum* 3D7, MRA-102, deposited by DJ Carucci; *P. falciparum* 7C46, MRA-172, deposited by TE Wellems; *P. vivax* Chesson, MRA-383, deposited by WE Collins; *P. vivax* NAM/CDC, MRA-384, deposited by WE Collins; Genomic samples—MRA 731G, MRA 925G, MRA 102G, and MRA 172; *P. falciparum* Genomic DNA from *P. falciparum* FCR-3/Gambia, MRA-731G; Genomic DNA from *P. falciparum* GB4, MRA-925G; *P. falciparum* Genomic DNA from *P. falciparum* 3D7, MRA-102G; and *P. falciparum* Genomic DNA—*P. falciparum* 7C46, MRA-172G.

**Whole mouth-stimulated saliva and negative blood samples.** Negative blood samples were obtained through the New York University Medical Center, and whole mouth-stimulated saliva (WMSS) was collected<sup>14</sup> at the Bluestone Research Center, New York University College of Dentistry, as previously described, using protocols approved by the New York University Langone School of Medicine IRB #05-51. As this research utilized existing, deidentified specimens, it was exempted from the requirement to obtain IRB approval under §46.101, b, (4).

**Collectors.** The following are the sample collection devices used Puritan HydraFlock (Puritan Diagnostics, Catalog #—25-3406-H), 4N6FLOQSwabs (COPAN Flock Technologies, Catalog #—4479429), and OraQuick ADVANCE HIV-1/2 kit (OraSure Technologies Inc.—Buffer and microloop).

**LAMP primers.** The primers specific for *P. falciparum* (Table 1) targeted the mitochondrial cytochrome oxidase subunit 1 gene (GenBank #AB570973.1) were optimized by varying the concentrations of each primer pair individually in the master mix, and the optimal concentration was selected based on the shortest  $C_t$  value. Primers were synthesized commercially (Sigma-Aldrich).

**Amplification facilitators/enhancers.** Bovine serum albumin (BSA) 2 mg/mL—BSA Protein Assay Standard (Thermo Scientific: Catalog #23209); BSA heat shock fraction, protease free, fatty acid free, essentially globulin free, pH 7, ≥98% (10 mg/mL—Sigma Catalog #A-7030); fraction V (10 mg/mL—Sigma Catalog #A-9418); albumin, from bovine serum (10 mg/mL—Sigma Catalog #A-3294); MSD blocker A (8 mg/mL—Meso Scale Discovery Catalog #R93AA-1); ethylenediaminetetraacetic acid (EDTA) (1.5 mg/mL—Sigma Catalog #EDS-500G); sodium citrate tribasic dihydrate (3.2%—Sigma Catalog #S4641-500G); glycerol (10%—Alfa Aesar Catalog #—J16059); SuperSignal West Pico Stable Peroxide Solution (Thermo Scientific Catalog #34077);  $MgCl_2$  (2 mM—Fisher Scientific Catalog #M33-500).

### DNA isolation.

*Dried blood spots/dried saliva spots.* Spots of infected blood and saliva (Malaria Institute of Macha) were dried on Whatman filter paper. A Harris UNI-CORE punch (Catalog #WB100029) was used to cut three 2-mm-diameter disks from each dried blood spot (DBS) containing *P. falciparum* 3D7 at applied concentrations of  $10^0$ ,  $10^3$ , and  $10^6$  parasites/ $\mu$ L and placed in 1.5-mL polyethylene microfuge tubes.<sup>15</sup> Parasite DNA was extracted from the DBS using QIAamp DNA Mini Kit (QIAGEN) (Catalog #51304) as per

**Table 1.** LAMP primer sequences for *P. falciparum*.

<i>P. falciparum</i> (mitochondrial cytochrome C oxidase subunit 1 gene) <sup>13</sup>	
FOP	CTCCATGTCGTCTCATCGC
BOP	AACATTTTTAGTCCCATGCTAA
FIP	ACCCAGTATATTGATATTGCGTGACAGCCTTGCAATAAATAATATCTAGC
BIP	AACTCCAGGCGTTAACCTGTAATGATCTTTACGTTAAGGGC
LF	CGGTGTGTACAAGGCAACAA
LB	GTTGAGATGGAACAGCCGG
<i>P. falciparum</i> and <i>P. vivax</i> (18S rRNA gene) <sup>12</sup>	
FOP	GTCGATCAGGAAGGTTTCA
BOP	GTAACGACTTCCCCATTGT
FIP	CCTGAGCACCTTAACTTCCCTATCCTTAAATCTCGTAACCATGC
BIP	TTACCGTCGGGCCGTATGATCGCTAGTGTGAGACTCCTA

**Abbreviations:** FOP, forward outer primer; BOP, back outer primer; FIP, forward inner primer; BIP, back inner primer; LF, forward loop primer; BLP, back loop primer.



the manufacturer's instructions. Briefly, lysis buffer (180  $\mu\text{L}$ ) was added, and the tubes were incubated with shaking (Eppendorf Thermomixer) for 60 minutes at 85°C followed by centrifugation at 14,000  $\times g$  and the addition of Proteinase K (400  $\mu\text{g}$ , Ambion Catalog #AM2548) to the lysate, which was then incubated at 56°C for 60 minutes. The DNA was eluted in 150  $\mu\text{L}$  of elution solution and quantified either spectrophotometrically (NanoDrop 2000 Spectrophotometer—Thermo Scientific) or fluorometrically (Quant-iT RiboGreen RNA Assay kit—Invitrogen: Catalog #R11490) as per the manufacturer's instructions and stored at -20°C.

**Malaria-positive blood DNA.** A stock of malaria genomic DNA was purified from malaria-positive blood (MPB) using Dynabeads SILANE Viral NA kit (Invitrogen) (Catalog #—37011D) as per the manufacturer's instructions to be used as an external positive control and standard.


**Isothermal amplification (LAMP).** Infected whole blood was heated at ~90°C for five minutes to lyse blood cells and parasites, releasing target DNA. LAMP reactions contained 17  $\mu\text{L}$  of a complete master mix (OptiGene: Catalog #ISO-004), 4  $\mu\text{L}$  of primers, and 4  $\mu\text{L}$  of sample DNA in a total volume of 25  $\mu\text{L}$ . OptiGene Isothermal master mix was used for all experiments and required only the addition of primers and target nucleic acid. The *P. falciparum*-specific LAMP reaction mix contained final concentrations of 0.2  $\mu\text{M}$  for outer primers, 1.6  $\mu\text{M}$  for inner primers, and 0.8  $\mu\text{M}$  for the loop primers. The *P. vivax*-specific LAMP reaction mix contained final concentrations of 1.5  $\mu\text{M}$  for outer primers and 2.5  $\mu\text{M}$  for inner primers and did not require loop primers. Reactions were followed in real time at 65°C for 30 minutes using either a Genie II or III instrument (OptiGene/Pro-Lab Diagnostics) and analyzed using Genie Explorer Software (OptiGene). Amplification was confirmed by observing the banding patterns after electrophoresis on 2% agarose gels stained with ethidium bromide.

## Results

**Detection using dried blood spots.** DNA isolated from DBS spotted with 10<sup>0</sup>, 10<sup>3</sup>, or 10<sup>6</sup> parasites/ $\mu\text{L}$  yielded concentrations of 1.7–2.0 ng/ $\mu\text{L}$ , respectively. The *P. falciparum* mitochondrial cytochrome oxidase subunit 1 gene was readily detected using LAMP (Fig. 1).

**Amplification without DNA isolation.** Experiments using MPB directly for LAMP were carried out to test the possibility of eliminating a DNA isolation step. Our studies indicated that a 1:1,000 dilution of blood allowed nucleic acid amplification with detection in real time (Fig. 2A). Although undiluted (1 $\times$ ) and 1:10 dilutions of blood were not visualized by real-time fluorescence, amplification did occur as verified by agarose gel electrophoresis of the amplification reaction products (Fig. 2B). The apparent inhibition of real-time amplification was attributed to fluorescence quenching by blood proteins.

**Parasite concentration determination.** The gold standard used for diagnosing malaria is microscopic observation



**Figure 1.** LAMP of DNA isolated from DBS showing real-time amplification in the positive control (genomic *Plasmodium* DNA) and amplification from DNA isolated from DBS containing 10<sup>3</sup> and 10<sup>6</sup> parasites/ $\mu\text{L}$ .

of thin and thick blood-smear slides, where the number of parasites per microliter is counted. The samples obtained from BEI were not characterized with a parasite titer. DNA from the genomic sample MRA 731G, as a representative MPB, was isolated and used to create a standard curve of DNA concentration as a function of the respective real-time amplification cross-over thresholds ( $C_t$ ) values observed from real-time amplification (Fig. 3). This allowed calculating the DNA concentration and estimating the parasite count. We calculated that the MRA 731 sample contained ~54 ng of parasite genomic DNA/ $\mu\text{L}$  blood.


Mu et al reported that the *P. falciparum* genome consists of ~23  $\times 10^6$  bp.<sup>16</sup> Dolezel et al<sup>17</sup> calculated the parasite's DNA content in picograms by the following formula:

$$1 \text{ parasite} = \frac{\text{Genome size (bp)}}{0.978 \times 10^9 \text{ pg/bp}}$$

Thus, 1 parasite = 23  $\times 10^6$  bp = 0.0235 pg. This formula and the concentration were determined from the amplification standard curve (Fig. 3); 1 ng of DNA contains ~42,553 parasites and 1  $\mu\text{L}$  of MRA 731 blood sample contains ~2,297,862 parasites.

The number of parasites in 1  $\mu\text{L}$  of MPB was also determined by the isolation of DNA from all the MPB samples using the Dynabeads SILANE viral NA kit. The isolated DNA was quantified using the Quant-iT RiboGreen assay kit, and the number of parasites was calculated (Supplementary Table 1). The values obtained by the isolation of DNA from MPB (MRA 731) using Dynabeads (~36 ng/ $\mu\text{L}$ ) and from the standard curve (Fig. 3B, ~54 ng/ $\mu\text{L}$ ) were considered similar when taking into account the efficiency of extraction and recovery by the Dynabeads SILANE Viral NA kit.

**Real-time LAMP.** Blood samples were diluted to eliminate fluorescence quenching resulting from blood proteins in order to follow the amplification in real time. Blood was diluted 1,000-fold in PBS and then serially diluted 10-fold up




**Figure 2. (A)** Direct LAMP of MPB without prior DNA isolation. Serial dilution of blood samples from 1:1,000 to 10,000 dilutions allowed following the amplification with real-time detection of fluorescence. However, smaller dilutions of blood (ie, 1× and 1:10) showed an apparent lack of amplification in real time. It should be noted that a dilution of 1:100 was not consistently sufficient to allow real-time detection depending on the blood sample. **(B)** Image of the agarose gel electrophoresis of the samples amplified in **(A)**. All of the samples showed the characteristic ladder pattern for LAMP after isothermal amplification.

to  $1:10^8$  to determine the lowest dilution detectable by LAMP. The lowest dilution detected was  $1 \times 10^6$  of MPB in water (Fig. 4), which is equivalent to 1.5 parasites/ $\mu\text{L}$  of MPB or 0.01 parasites/ $\mu\text{L}$  in the 25  $\mu\text{L}$  of reaction mix. This experiment supports the high sensitivity of LAMP, and its use for diagnosing recently infected asymptomatic patients.

**Enhancers.** Methods to reduce or eliminate the apparent fluorescence quenching of blood in real-time LAMP besides dilution were explored. Previous reports indicated that a buffer composed of 320 nM of saccharose, 5 nM  $\text{MgCl}_2$ , 1% Triton X-100, 10 mM Tris-HCl (pH 7.5) was successful in using a whole blood sample for amplification by PCR in the diagnosis of brucellosis.<sup>18</sup> Hypotonic solution, increased pH,


and  $\text{MgCl}_2$  concentration have also been successfully used in the genotypic identification of closely related alleles.<sup>19</sup> The addition of anticoagulants was shown to be helpful in the amplification of human hemochromatosis and *apoE* genes. Na-heparin, a commonly used anticoagulant for the collection of blood from humans, was cited to be better than using either EDTA or sodium citrate.<sup>20</sup>

The addition of BSA (0.24  $\mu\text{M}$ ) or glycerol (0.87  $\mu\text{M}$ ) was confirmed in our system to facilitate DNA amplification.<sup>21–24</sup> Heating whole blood samples in a microwave<sup>25</sup> or at 99°C for 10 minutes were also reported to be successful for LAMP of the *P. falciparum* 18S ribosomal RNA gene.<sup>26</sup> Other reagents used as enhancers included EDTA (410  $\mu\text{M}$ ),



**Figure 3. (A)** LAMP as a function of concentration of genomic DNA sample MRA-731G. **(B)** Graph of the resulting  $C_t$  values as a function of MRA-731 DNA concentration (ng/ $\mu\text{L}$ ) ( $n = 7$ ). **(C)** Annealing curves of the genomic sample MRA-731 for each dilution yielded a single amplicon product.







**Figure 4.** LAMP curves for a serial dilution of MPB blood (MRA-731) from 1:1,000 to 10,000,000.

Na citrate (0.01  $\mu$ M),  $MgCl_2$  (0.08  $\mu$ M), and  $H_2O_2$  (0.04%) and observed the following:  $C_t$ 's: BSA—630 seconds, glycerol solution—1,230 seconds, EDTA – 1,200 seconds, hydrogen peroxide solution—1,305 seconds, and  $MgCl_2$ —1,560 seconds (Fig. 5A). BSA was prepared by *initial fractionation by heat shock*. The amplification of 0.8% MPB (50  $\mu$ L of the 1:10 diluted MPB) was performed after incubation with shaking at 70°C for 15 minutes with the enhancer tested. BSA was considered the best facilitator based on amplification starting earlier than for the other compounds tested (Fig. 5). The observed annealing temperature was consistently 87.7°C for all samples, suggesting that no alternative products were produced (Fig. 5B).

**Heat lysis.** Heat treatment of blood was found to facilitate LAMP without the need for isolating parasite DNA.<sup>25,26</sup> We examined the temperature range from 75°C to 95°C and show that dilution with PBS of MPB (1:40), followed by heating for five minutes at 90°C, gave reproducible amplification (Fig. 6).




**Figure 5.** (A) LAMP of MPB treated with agents indicating that BSA facilitates amplification more efficiently than other agents when heated at 70°C for 15 minutes. (B) Image of the electrophoresis gel of the LAMP amplified treated MPB.




**Figure 6.** Effect of temperature on the LAMP cross-over threshold (C<sub>t</sub>). All incubations were for 5 minutes at the indicated temperature, followed by a 4-μL aliquot amplified using LAMP.

**Detection of parasites from saliva.** WMSS samples were spiked with the malarial genomic sample MRA-172, and Hydraflock and Copan collectors were submerged in 500 μL of 0.1 ng/μL (~4,255 parasites/μL) of spiked saliva for one minute, transferred to a Mobicol column (Fig. 7A), inserted in a microfuge tube, and centrifuged at 2,400 rpm for five minutes, and 4 μL of eluted DNA was (Fig. 7B) taken for amplification. Both the collectors transferred a volume of ~150 μL with an average of 96% volume recovery. Both collectors picked up ~50% of the genomic sample, though only 8% and 0.02% of the total sample were recovered from the Hydraflock and Copan collectors, respectively (Figs. 7 and 8).

***P. falciparum* detection specificity.** We targeted the *P. falciparum* mitochondrial cytochrome oxidase subunit 1 gene, which is specific for *P. falciparum* and does not amplify



**Figure 7.** (A) Mobicol column with loaded Copan collector head. (B) Mobicol assembly post-centrifugation with eluted sample after centrifugation from the Copan collector head suspended in Mobicol column inserted in the 1.5-mL Eppendorf centrifuge tube.



**Figure 8.** LAMP of spiked WMSS samples recovered from Hydraflock and Copan collectors.


*P. vivax* genomic DNA (MRA 383 and MRA 384; Fig. 9). Primers that target and amplify the 18S rRNA gene present in all *Plasmodium* species (*falciparum*, *vivax*, *malaria*, and *ovale*) have been reported.<sup>12,27</sup>

**Discussion**

These results suggest that the diagnosis of malaria can be achieved by using LAMP of DBS isolated from infected individuals (Fig. 1). MPB was used to demonstrate that nucleic acid isolation was not required for amplification, although the dilution of parasite-infected blood needs to be diluted to prevent quenching or inhibition of the amplification reaction (Fig. 2A and B). A 1,000 fold dilution of the blood samples was required to consistently detect the *Plasmodium* target with real-time detection without first isolating the parasite DNA (Fig. 4). BSA was found to be the best agent (Fig. 5), and together with preparing the blood/parasite sample for nucleic acid amplification by dilution and heat lysis were the best for facilitating amplification (Fig. 6). Target specificity was demonstrated for *P. falciparum*. A proof-of-concept study showed that malaria could be diagnosed from oral samples collected by cheek-swab collectors (Figs. 7 and 8).

Primers that target highly conserved mitochondrial sequences in *Plasmodium* species<sup>13,28</sup> and targeting the highly conserved Pvr64 family of genes and the alpha-tubulin gene in *P. vivax*<sup>29,30</sup> have also been reported. These are being explored for their ability to differentiate species using LAMP (Fig. 9). The advantage of the mitochondrial sequences is that they are highly conserved, which facilitates the distinguishing of *falciparum* in a mixture of genetic variation.

We designed a rapid LAMP-based assay for the detection of *Plasmodium* parasites using both blood and oral fluid without sample purification. The optimized protocol is suitable for POC diagnosis of malaria infection by *P. falciparum*. Heat lysis coupled with dilution allows the amplification of parasites without the need to first purify target DNA with



**Figure 9. (A)** LAMP detection of *P. falciparum* DNA using LAMP primers targeted to the parasite's mitochondrial cytochrome oxidase subunit 1 gene. The *P. falciparum*-specific primers did not amplify two different samples of *P. vivax* DNA. **(B)** LAMP detects both *P. falciparum* and *P. vivax* DNA when targeting the 18S rRNA gene present in all *Plasmodium* species.

both high sensitivity and specificity from a subject's blood or saliva samples. The technique is rapid (ie, ~30 minutes to result) with a detection limit of ~1–2 parasites/ $\mu\text{L}$  and can detect either *P. falciparum* alone or differentially with *P. vivax* using primers directed against ribosomal RNA. BSA was used as an amplification enhancer, but further study needs to be done to optimize its use.

### Acknowledgments

Dried blood and saliva spots were generously provided by Dr. Sungano Mharakurwa, Malaria Institute of Macha, Choma. Jane Carlton, New York University, New York, NY, USA, is acknowledged for her generous contribution of parasite blood samples.

### Author Contributions

Conceived and designed the experiments: SSM, EG, DM, and YSYO. Analyzed the data: SSM, CAB, and WRA. Wrote the first draft of the manuscript: SSM. Contributed to the writing of the manuscript: SSM, CAB, EG, WRA, DM, and YSYO. Agreed with the manuscript results and conclusions: SSM, CAB, EG, WRA, DM, and YSYO. Jointly developed the structure and arguments for the paper: SSM, CAB, EG, WRA, DM, and YSYO. Made critical revisions and approved the final version: DM and WRA. All authors reviewed and approved the final manuscript.

### REFERENCES

- World Health Organization. *World Malaria Report 2014*. Geneva, Switzerland: World Health Organization; 2014.
- Snounou G, Renia L. The vaccine is dead—long live the vaccine. *Trends Parasitol*. 2007;23(4):129–132.
- Walensky RP, Paltiel AD, Losina E, et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. *Clin Infect Dis*. 2010;51(4):392–400.
- Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant *Plasmodium falciparum* malaria. *Nature*. 2014;505(7481):50–55.

- Chen D, Mauk M, Qiu X, et al. An integrated, self-contained microfluidic cassette for isolation, amplification, and detection of nucleic acids. *Biomed Microdevices*. 2010;12(4):705–719.
- Kim J, Byun D, Mauk MG, et al. A disposable, self-contained PCR chip. *Lab Chip*. 2009;9(4):606–612.
- Liu C, Mauk MG, Hart R, et al. A self-heating cartridge for molecular diagnostics. *Lab Chip*. 2011;11(16):2686–2692.
- Liu C, Qiu X, Ongagna S, et al. A timer-actuated immunoassay cassette for detecting molecular markers in oral fluids. *Lab Chip*. 2009;9(6):768–776.
- Paris DH, Imwong M, Faiz AM, et al. Loop-mediated isothermal PCR (LAMP) for the diagnosis of falciparum malaria. *Am J Trop Med Hyg*. 2007;77(5):972–976.
- Ghayour Najafabadi Z, Oormazdi H, Akhlaghi L, et al. Detection of *Plasmodium vivax* and *Plasmodium falciparum* DNA in human saliva and urine: loop-mediated isothermal amplification for malaria diagnosis. *Acta Trop*. 2014;136:44–49.
- Mohon AN, Elahi R, Khan WA, et al. A new visually improved and sensitive loop mediated isothermal amplification (LAMP) for diagnosis of symptomatic *falciparum* malaria. *Acta Trop*. 2014;134:52–57.
- Han ET, Watanabe R, Sattabongkot J, et al. Detection of four *Plasmodium* species by genus- and species-specific loop-mediated isothermal amplification for clinical diagnosis. *J Clin Microbiol*. 2007;45(8):2521–2528.
- Polley SD, Mori Y, Watson J, et al. Mitochondrial DNA targets increase sensitivity of malaria detection using loop-mediated isothermal amplification. *J Clin Microbiol*. 2010;48(8):2866–2871.
- Phelan JA, Abrams WR, Norman RG, et al. Design aspects of a case-control clinical investigation of the effect of HIV on oral and gastrointestinal soluble innate factors and microbes. *PLoS One*. 2014;9(11):e112901.
- Ongagna-Yhombi SY, Corstjens P, Geva E, et al. Improved assay to detect *Plasmodium falciparum* using an uninterrupted, semi-nested PCR and quantitative lateral flow analysis. *Malar J*. 2013;12:74.
- Mu J, Seydel KB, Bates A, et al. Recent progress in functional genomic research in *Plasmodium falciparum*. *Curr Genomics*. 2010;11(4):279–286.
- Dolezel J, Bartos J, Voglmayr H, et al. Nuclear DNA content and genome size of trout and human. *Cytometry A*. 2003;51(2):127–128. Author reply 129.
- Morata P, Queipo-Ortuno MI, de Dios Colmenero J. Strategy for optimizing DNA amplification in a peripheral blood PCR assay used for diagnosis of human brucellosis. *J Clin Microbiol*. 1998;36(9):2443–2446.
- Zhu J, Chen L, Mao Y, et al. Multiplex allele-specific amplification from whole blood for detecting multiple polymorphisms simultaneously. *Genet Test Mol Biomarkers*. 2013;17(1):10–15.
- Grunenwald H. Direct PCR from whole blood. *Epicentre*. 2013;7(4):10–12.
- Abu Al-Soud W, Radstrom P. Effects of amplification facilitators on diagnostic PCR in the presence of blood, feces, and meat. *J Clin Microbiol*. 2000;38(12):4463–4470.
- Kreder CA. Relief of amplification inhibition in PCR with bovine serum albumin or T4 gene 32 protein. *Appl Environ Microbiol*. 1996;62(3):1102–1106.
- Nagai M, Yoshida A, Sato N. Additive effects of bovine serum albumin, dithiothreitol, and glycerol on PCR. *Biochem Mol Biol Int*. 1998;44(1):157–163.
- Farell EM, Alexandre G. Bovine serum albumin further enhances the effects of organic solvents on increased yield of polymerase chain reaction of GC-rich templates. *BMC Res Notes*. 2012;5:257.



25. Sandford AJ, Pare PD. Direct PCR of small genomic DNA fragments from serum. *Biotechniques*. 1997;23(5):890–892.
26. Poon LL, Wong BW, Ma EH, et al. Sensitive and inexpensive molecular test for falciparum malaria: detecting *Plasmodium falciparum* DNA directly from heat-treated blood by loop-mediated isothermal amplification. *Clin Chem*. 2006; 52(2):303–306.
27. Aydin-Schmidt B, Xu W, Gonzalez IJ, et al. Loop mediated isothermal amplification (LAMP) accurately detects malaria DNA from filter paper blood samples of low density parasitaemias. *PLoS One*. 2014;9(8):e103905.
28. Tao ZY, Zhou HY, Xia H, et al. Adaptation of a visualized loop-mediated isothermal amplification technique for field detection of *Plasmodium vivax* infection. *Parasit Vectors*. 2011;4:115.
29. Patel JC, Oberstaller J, Xayavong M, et al. Real-time loop-mediated isothermal amplification (RealAmp) for the species-specific identification of *Plasmodium vivax*. *PLoS One*. 2013;8(1):e54986.
30. Dinzouna-Boutamba SD, Yang HW, Joo SY, et al. The development of loop-mediated isothermal amplification targeting alpha-tubulin DNA for the rapid detection of *Plasmodium vivax*. *Malar J*. 2014;13:248.





## Supplementary Material

**Supplementary Table 1.** Calculation of the number of parasites present in a microliter of blood.

MPB	CONCENTRATION (ng/ $\mu$ L)	NUMBER OF PARASITES/ $\mu$ L
MRA-731	36	15,31,908
MRA-925	10	4,25,530
MRA-102	23	9,78,719
MRA-172	2	85,106
MRA-383	43	18,29,779
MRA-384	62	26,38,286